Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Equivalents (2016 - 2025)

Rockwell Medical's Cash & Equivalents history spans 16 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 31.61% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, down 31.61%, while the annual FY2025 figure was $10.7 million, 31.61% down from the prior year.
  • Cash & Equivalents reached $10.7 million in Q4 2025 per RMTI's latest filing, down from $13.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $35.7 million in Q1 2021 to a low of $6.6 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $15.0 million, with a median of $12.1 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: crashed 72.72% in 2021, then surged 74.35% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $13.3 million in 2021, then decreased by 23.93% to $10.1 million in 2022, then dropped by 11.08% to $9.0 million in 2023, then surged by 74.35% to $15.7 million in 2024, then tumbled by 31.61% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for RMTI's Cash & Equivalents are $10.7 million (Q4 2025), $13.6 million (Q3 2025), and $12.5 million (Q2 2025).